Author:
Sia Joseph,D’Souza Criselle,Castle Becky,Huang Yu-Kuan,Aw Yeang Han,Idrizi Rejhan,Jana Metta,Siva Shankar,Phillips Claire,Neeson Paul J.
Reference47 articles.
1. Epidemiology of brain metastases and leptomeningeal disease;N Lamba;Neuro-Oncology,2021
2. Presentation, patterns of care, and survival in patients with brain metastases;C Nieder;Cancer,2011
3. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study;H A Tawbi;The Lancet Oncology,2021
4. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial;K Margolin;Lancet Oncol,2012
5. Pembrolizumab for management of patients with NSCLC and brain metastases: longterm results and biomarker analysis from a non-randomised, open-label, phase 2 trial;S B Goldberg;Lancet Oncol,2020